Orbital implant receives innovation award

Article

The new AlphaSphere Orbital Implant ophthalmic device has been awarded the 2010 Alpha Award for Innovation In Engineering & Technology presented by the Engineering Society of Detroit.

The new AlphaSphere Orbital Implant ophthalmic device has been awarded the 2010 Alpha Award for Innovation In Engineering & Technology presented by the Engineering Society of Detroit.

Art Brodie, Executive Vice President, Business Development at Addition Technology, the maker of the product said: “We view the engineering, materials and design of the AlphaSphere device to be a quantum leap forward in orbital implant technology. Although AlphaSphere was only launched in the second half of 2009, we have already seen surgeons at Bascom Palmer, Yale and Mass. Eye & Ear to name a few begin to use the device, and though the results are short-term, the light-weight, smooth and bio-integratable characteristics have generated very favourable feedback.”

The implant is a new entry into an historical market that dates back to 1884. It is the first orbital implant device made from a novel poly-HEMA bio-material (PHEMA) that biointegrates into the eye socket capsule yet resists bio-integration in its posterior hemisphere to provide S motility to a prosthetic eye. Since the majority of its composition is water, AlphaSphere’s ability to provide compliance in matching natural organ tissue is claimed by its makers to be unique in comparison to other orbital implant products due to its soft, smooth and pliable exterior. A major feature is the ability to directly suture into the endo-skeletal, anterior surface.

www.AdditionTechnology.com will give you more information.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.